Skip to main content

Market Overview

Novartis Beefs Up Radioligand Portfolio With iTheranostics Deal

  • Just a week after acing Phase 3 study evaluating radioligand therapy in prostate cancer, Novartis AG (NYSE: NVS) is licensing the rights to develop and commercialize treatments based on a library of radioligand compounds from iTheranostics, a subsidiary of Sofie Biosciences.
  • These compounds target fibroblast activation protein or FAP, a cell surface protein found in low levels in healthy tissue but found in high levels in common cancers.
  • The agreement with Sofie includes the rights to develop the radioligand assets for imaging and therapeutic use.
  • Earlier today, Lantheus Holdings Inc acquired rights to NTI-1309, a PET oncology imaging agent that targets fibroblast activation protein.
  • Price Action: NVS shares are trading 0.6% lower at $86.85 in market trading hours on the last check Tuesday.

Related Articles (NVS)

View Comments and Join the Discussion!

Posted-In: oncologyBiotech M&A News Health Care Contracts Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at